Safety of Candesartan, Amlodipine, and Atorvastatin in Combination: Interaction Study in Healthy Subjects-Reference-Cited by-同舟云学术

Safety of Candesartan, Amlodipine, and Atorvastatin in Combination: Interaction Study in Healthy Subjects

Published:2020-05-10 Issue:2 Volume:10 Page:190-197
ISSN:2160-763X
Container-title:Clinical Pharmacology in Drug Development
language:en
Short-container-title:Clinical Pharmacology in Drug Development

Author:

Gundlach Kristina¹,Wolf Katharina¹,Salem Isam²,Randerath Olaf³,Seiler Dan¹

Affiliation:

1. Midas Pharma GmbH Ingelheim Germany

2. International Pharmaceutical Research Center Amman Jordan

3. Apontis Pharma GmbH & Co. KG Monheim Germany

Funder

Midas Pharma GmbH

Publisher

Wiley

Subject

Pharmacology (medical),Pharmaceutical Science

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/cpdd.787

Reference23 articles.

1. World Health Organization.https://www.who.int/news-room/fact-sheets/detail/cardiovascular-diseases-(cvds). Updated May 2017. Accessed July 11 2019.

2. High rates of co‐occurrence of hypertension, elevated low‐density lipoprotein cholesterol, and diabetes mellitus in a large managed care population;Selby JV;Am J Manag Care,2004

3. Clinical Practice Guidelines for the Management of Hypertension in the Community

4. 2014 Evidence-Based Guideline for the Management of High Blood Pressure in Adults

5. 2018 ESC/ESH Guidelines for the management of arterial hypertension

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Pharmacokinetic Comparison of a Fixed-Dose Combination of Candesartan Cilexetil/Amlodipine/Atorvastatin Versus Co-administration of Individual Formulations in Healthy Participants;Advances in Therapy;2024-05-21

2. The power of High Impact Amplitude Manipulation (HIAM) technique for extracting the basic spectra of two Fixed-dose combinations (FDC) -Spectrophotometric purity analysis via spectral contrast angle;Spectrochimica Acta Part A: Molecular and Biomolecular Spectroscopy;2022-05